Drug Profile


Alternative Names: ASC-01; Sertraline/aripiprazole

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Amines; Antidepressants; Chlorobenzenes; Mood stabilisers; Naphthalenes; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D2 receptor antagonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Major depressive disorder

Most Recent Events

  • 01 Sep 2016 Otsuka Pharmaceutical completes a phase-III trial for Major depressive disorder in Japan, South Korea, Taiwan, Malaysia and Australia (NCT02046564)
  • 01 Dec 2015 Phase-III development for Major depressive disorder is ongoing in Japan, South Korea, Taiwan, Malaysia and Australia (NCT02046564)
  • 01 Feb 2014 Phase-III clinical trials in Major depressive disorder in South Korea, Taiwan, Malaysia and Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top